Syverson Strege & Co Acquires Shares of 13,602 Pfizer Inc. $PFE

Syverson Strege & Co acquired a new stake in Pfizer Inc. (NYSE:PFE) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 13,602 shares of the biopharmaceutical company’s stock, valued at approximately $330,000.

Other large investors also recently modified their holdings of the company. GKV Capital Management Co. Inc. purchased a new stake in shares of Pfizer in the 1st quarter valued at approximately $27,000. Curio Wealth LLC boosted its holdings in shares of Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,098 shares in the last quarter. North Capital Inc. acquired a new position in shares of Pfizer in the 1st quarter valued at $28,000. Bayforest Capital Ltd acquired a new position in shares of Pfizer in the 1st quarter valued at $28,000. Finally, Harbor Asset Planning Inc. acquired a new position in shares of Pfizer in the 2nd quarter valued at $29,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

PFE has been the subject of several research analyst reports. Bank of America upped their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Sanford C. Bernstein restated a “market perform” rating and issued a $30.00 target price on shares of Pfizer in a report on Friday. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Citigroup upped their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Finally, Morgan Stanley decreased their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $28.24.

Pfizer Stock Up 1.6%

Shares of NYSE:PFE opened at $24.68 on Friday. The stock has a market cap of $140.29 billion, a P/E ratio of 13.13, a P/E/G ratio of 0.81 and a beta of 0.55. The firm has a fifty day moving average price of $24.77 and a 200 day moving average price of $24.27. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $28.64.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. Pfizer’s dividend payout ratio is presently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.